Last reviewed · How we verify
Antiretroviral medications+Isoniazid prophylaxis — Competitive Intelligence Brief
phase 3
Antiretroviral combination therapy + antimycobacterial prophylaxis
Infectious Disease / Virology
Small molecule
Live · refreshed every 30 min
Target snapshot
Antiretroviral medications+Isoniazid prophylaxis (Antiretroviral medications+Isoniazid prophylaxis) — French National Agency for Research on AIDS and Viral Hepatitis. This combination uses antiretroviral drugs to suppress HIV replication while isoniazid prophylaxis prevents tuberculosis infection in co-infected patients.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antiretroviral medications+Isoniazid prophylaxis TARGET | Antiretroviral medications+Isoniazid prophylaxis | French National Agency for Research on AIDS and Viral Hepatitis | phase 3 | Antiretroviral combination therapy + antimycobacterial prophylaxis |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antiretroviral combination therapy + antimycobacterial prophylaxis class)
- French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antiretroviral medications+Isoniazid prophylaxis CI watch — RSS
- Antiretroviral medications+Isoniazid prophylaxis CI watch — Atom
- Antiretroviral medications+Isoniazid prophylaxis CI watch — JSON
- Antiretroviral medications+Isoniazid prophylaxis alone — RSS
- Whole Antiretroviral combination therapy + antimycobacterial prophylaxis class — RSS
Cite this brief
Drug Landscape (2026). Antiretroviral medications+Isoniazid prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/antiretroviral-medications-isoniazid-prophylaxis. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab